He also said...
He also took issue with another design approach that has recently gained favor in the field:
adaptive trials where decisions are made on whether to proceed with a given compound or dose
based on cognitive assessments done at early, interim time points. Adaptive trials have proven to
be very powerful for diseases such as cancer where there are clear and hard biomarkers of
disease progression. But Aisen said that measures of cognition are too noisy to predict, at an
early time point, what the final outcome will be.
News 
Market Data 
Discover 
AI
